Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
Healthcare
$7.51 +5.14%
+$0.45 today
- Market cap
- $53.05M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
52W Low $6.47High $12.74
Volume 0.00M
Average 0.05M
Income Statement
Follow revenue through to earnings.
Revenue
$43.77M
FY 2025 · Annual
+589.9% YoYOperating Income
-$41.98M
FY 2025 · Annual
Net Income
-$35.04M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 6.34M | 43.77M |
| Cost of Revenue | 1.5M | 0 | 0 | 0 | 1.54M |
| Gross Profit | (1.5M) | 0 | 0 | 6.34M | 42.23M |
| Gross Margin | — | — | — | 100.0% | 96.5% |
| Research & Development | 51.19M | 59.2M | 52.14M | 41.21M | 56.04M |
| Selling, General & Admin | 22.36M | 29.95M | 27M | 24.78M | 29.71M |
| Operating Expenses | 73.55M | 89.15M | 79.13M | 66.93M | 84.21M |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| EBITDA | (73.7M) | (86.38M) | (74.5M) | (58M) | (33.5M) |
| EBITDA Margin | — | — | — | -914.3% | -76.5% |
| Operating Income | (75.04M) | (89.15M) | (79.13M) | (60.58M) | (41.98M) |
| Operating Margin | — | — | — | -954.9% | -95.9% |
| Interest Income | 600 | 0 | 0 | 0 | 3.4M |
| Interest Expense | 600K | 0 | 0 | 100K | 0 |
| Other Income / Expenses | (756K) | 927K | 2.73M | 2.34M | 6.95M |
| Income Before Tax | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Pre-Tax Margin | — | — | — | -918.0% | -80.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Net Margin | — | — | — | -918.0% | -80.1% |
| EPS (Basic) | (189.28) | (45.08) | (38.92) | (15.26) | (4.19) |
| EPS (Diluted) | (189.28) | (45.08) | (38.92) | (15.26) | (4.19) |
| 400.45K | 1.96M | 1.96M | 3.82M | 83.59M | |
| 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
XLO Earnings Waterfall · TTM
NASDAQ:XLO · Revenue to Net Income
Key Ratios
EPS$-5.65
Gross Margin51.9%
Net Margin-70.3%
P/E Ratio-5.1
P/S Ratio43.5
Analysis
$53.5M of revenue converted into -$31.3M of net income for the selected period. Gross margin is 51.9% and net margin is -70.3%, showing how much revenue survives after costs and taxes. EPS is $-5.65, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| S-8 | S-8 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 |
How much revenue does XLO generate?
Xilio Therapeutics, Inc. (XLO) reported $43.77M of revenue in fiscal 2025.
Is XLO profitable?
Xilio Therapeutics, Inc. (XLO) reported -$35.04M of net income, with a net margin of -80.1%.
Continue the stock analysis
Jump to another research area for this company.